You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR GRANISETRON HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Granisetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003213 ↗ Drugs to Reduce the Side Effects of Chemotherapy Completed Swiss Group for Clinical Cancer Research Phase 3 1996-05-01 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy.
NCT00004219 ↗ Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status Simbec Research Phase 3 1969-12-31 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and vomiting. PURPOSE: Randomized phase III trial to compare the effectiveness of lerisetron with that of granisetron in preventing nausea and vomiting in men who are being treated with radiation therapy for stage I seminoma.
NCT00005024 ↗ Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease Unknown status National Cancer Institute (NCI) Phase 3 1969-12-31 RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo in preventing nausea and vomiting after chemotherapy in patients who have malignant disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Granisetron Hydrochloride

Condition Name

Condition Name for Granisetron Hydrochloride
Intervention Trials
Chemotherapy-Induced Nausea and Vomiting 13
Nausea 12
Vomiting 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Granisetron Hydrochloride
Intervention Trials
Vomiting 62
Nausea 51
Postoperative Nausea and Vomiting 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Granisetron Hydrochloride

Trials by Country

Trials by Country for Granisetron Hydrochloride
Location Trials
United States 111
China 22
Egypt 12
Canada 7
Korea, Republic of 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Granisetron Hydrochloride
Location Trials
Michigan 7
Illinois 7
California 6
Pennsylvania 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Granisetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Granisetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 21
Phase 3 27
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Granisetron Hydrochloride
Clinical Trial Phase Trials
Completed 71
Recruiting 17
Unknown status 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Granisetron Hydrochloride

Sponsor Name

Sponsor Name for Granisetron Hydrochloride
Sponsor Trials
Prostrakan Pharmaceuticals 9
National Cancer Institute (NCI) 8
Merck Sharp & Dohme Corp. 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Granisetron Hydrochloride
Sponsor Trials
Other 119
Industry 57
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Granisetron Hydrochloride: Clinical Trials, Market Analysis, and Projections

Last updated: January 7, 2025

Introduction

Granisetron hydrochloride is a potent antiemetic drug used primarily to prevent nausea and vomiting induced by chemotherapy, radiation therapy, and postoperative recovery. Here, we will delve into the clinical trials, market analysis, and projections for this crucial medication.

Clinical Trials Overview

Chemotherapy-Induced Nausea and Vomiting (CINV)

Granisetron hydrochloride has been extensively tested in clinical trials to evaluate its efficacy in preventing CINV. In a double-blind, randomized trial, granisetron hydrochloride tablets (1 mg twice a day and 2 mg once a day) were compared to placebo and other antiemetic treatments. The results showed that granisetron hydrochloride was significantly superior to placebo in all efficacy parameters, including complete response, no vomiting, no nausea, and total control[1].

For instance, in a trial involving 119 cancer patients receiving high-dose cisplatin, granisetron hydrochloride tablets (1 mg twice a day) demonstrated a complete response rate of 52%, no vomiting rate of 56%, and no nausea rate of 45%, all of which were statistically superior to placebo[1].

Extended-Release Formulation

The FDA approved an extended-release formulation of granisetron (Sustol) based on a multicenter double-blind trial involving 733 patients. This trial compared the efficacy of subcutaneous granisetron (10 mg) to intravenous palonosetron (0.25 mg). The results indicated that the extended-release granisetron was noninferior to palonosetron in both acute and delayed phases of CINV, providing protection for up to 5 days[4].

Radiation-Induced Nausea and Vomiting

In a double-blind randomized study, granisetron hydrochloride tablets (2 mg daily) were found to offer significantly greater antiemetic protection compared to conventional antiemetics in patients undergoing total body irradiation. The study showed that granisetron hydrochloride significantly prolonged the time to the first episode of vomiting and nausea[1].

Pharmacokinetics and Dosage

Hepatic Impairment

Pharmacokinetic studies have shown that in patients with hepatic impairment, the total clearance of granisetron hydrochloride is approximately halved compared to patients without hepatic impairment. However, due to the wide variability in pharmacokinetic parameters, dosage adjustment in patients with hepatic functional impairment is not necessary[1].

Pediatric Patients

In pediatric cancer patients (2 to 16 years of age), the pharmacokinetics of granisetron hydrochloride were found to be similar to those in adult patients when adjusted for body weight. This suggests that no specific dosage adjustments are needed for pediatric patients based on age alone[1].

Market Analysis

Market Size and Growth

The granisetron hydrochloride market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2 billion by 2031, growing at a CAGR of 5.2% from 2024 to 2031. This growth is driven by the increasing incidence of cancer, the need for efficient antiemetics, and advancements in drug delivery technologies[2].

Segmentation

The market is segmented based on application (oral tablets, injection solutions, patch formulations) and product (nausea and vomiting, chemotherapy-induced nausea, postoperative nausea). Geographically, the market is divided into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa[2].

Key Drivers

The market growth is primarily driven by the rising prevalence of cancer and the subsequent increase in chemotherapy and radiation treatments. Technological advancements in drug formulations, increased healthcare spending, and a focus on improving patient quality of life are also significant factors[2][5].

Competitive Landscape

The granisetron hydrochloride market includes both established and emerging players. The report provides extensive lists of prominent companies, their market entry year, and various market-related factors. Companies are investing in research and development to improve the efficacy and convenience of granisetron hydrochloride formulations[2].

Market Projections

Future Trends

The demand for granisetron hydrochloride is expected to rise significantly due to the increasing focus on patient-centric care and the development of better drug delivery systems. The growing preference for outpatient cancer treatments and advances in medical technology are also driving the market forward[2][5].

Regulatory Environment

Regulatory agencies such as the FDA and EMA have established standards for the approval and use of antiemetics, including granisetron hydrochloride. Compliance with these regulations drives pharmaceutical companies to invest in manufacturing and developing high-quality granisetron hydrochloride API[5].

Key Takeaways

  • Clinical Efficacy: Granisetron hydrochloride has demonstrated significant efficacy in preventing CINV and radiation-induced nausea and vomiting in clinical trials.
  • Market Growth: The market is expected to grow at a CAGR of 5.2% from 2024 to 2031, driven by increasing cancer incidence and advancements in drug delivery technologies.
  • Segmentation: The market is segmented by application, product, and geography, with a focus on improving patient quality of life.
  • Regulatory Compliance: Adherence to regulatory standards is crucial for the development and approval of granisetron hydrochloride formulations.

FAQs

Q: What is the primary use of granisetron hydrochloride?

A: Granisetron hydrochloride is primarily used to prevent nausea and vomiting induced by chemotherapy, radiation therapy, and postoperative recovery.

Q: What are the key findings from clinical trials on granisetron hydrochloride?

A: Clinical trials have shown that granisetron hydrochloride is significantly superior to placebo in preventing CINV and radiation-induced nausea and vomiting, with efficacy rates comparable to or better than other antiemetics like palonosetron.

Q: How does the extended-release formulation of granisetron hydrochloride work?

A: The extended-release formulation (Sustol) provides protection against CINV for up to 5 days, making it a novel option for managing delayed CINV, which is particularly challenging to control[4].

Q: What are the market drivers for granisetron hydrochloride?

A: The market is driven by the increasing incidence of cancer, advancements in drug delivery technologies, increased healthcare spending, and a focus on improving patient quality of life.

Q: What is the projected market size for granisetron hydrochloride by 2031?

A: The granisetron hydrochloride market is expected to reach USD 2 billion by 2031, growing at a CAGR of 5.2% from 2024 to 2031[2].

Sources

  1. FDA Label: Granisetron Hydrochloride Tablets - Clinical Trials and Pharmacokinetics[1].
  2. Market Research Intellect: Granisetron Hydrochloride Market Size and Forecast[2].
  3. GitHub: Granisetron Hydrochloride Market Report[3].
  4. OncLive: FDA Approves Extended-Release Granisetron for CINV[4].
  5. Verified Market Research: Granisetron HCl API Market Size, Share, Trends, Scope & Forecast[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.